Beta Blockers reduce Mortality in Heart Failure Patients with CKD, claims study
Current national guidelines recommend that clinicians treat patients with heart failure and left ventricular systolic dysfunction with β-adrenergic receptor blockers (β-blockers), based on robust evidence from several randomized clinical trials showing a reduction in mortality and morbidity. More than two-thirds of patients with heart failure also have chronic kidney disease (CKD), which independently increases the risk of adverse cardiovascular events and death.
According to a new study published in the American Journal of Kidney Diseases, β-blockers have been associated with a lower rate of mortality among incident hemodialysis patients with Heart failure.
To date,β-blockers are recommended for heart failure (HF) patients but their benefit in the dialysis population is uncertain. β-blockers are heterogeneous including concerning their removal by hemodialysis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.